« Return to News | Drug Sponsors

Merck restructures with job cuts

Tuesday, September 20, 2011 10:23 AM

A few weeks ago, Merck disclosed plans to trim another 12,000 to 13,000 jobs by the end of 2015 in order to save up to $1.5 billion. This is on top of previously announced cuts although efforts to reduce headcount are forcing managers to accelerate their plans, according to Pharmalot.

Merck’s US Market president Mark Timney released a memo informing staffers that cutting expenses by eliminating vacant positions, by itself, just isn’t sufficient to meet targets. And so a handful of departments should brace for layoffs that will be decided by the end of next month. These include marketing & customer solutions; managed markets & policy; strategy & commercial model innovation; and the meuropsychiatric and women’s healthcare specialty sales teams. These are located in Merck’s CIA-like headquarters in rural New Jersey. Volunteers, by the way, are encouraged to ‘hand raise’ if a package seems appealing.

The goal is to bring total headcount much closer to levels that existed before Schering-Plough was acquired; at the time, Merck employed about 53,000 people. As of the end of June, Merck employed about 91,000 people worldwide. Nonetheless, the move is certain to further undermine morale and his approach is prompting some criticism that Merck is being disingenuous about expressing concern for its employees.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.